Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (BCTX)
NASDAQ:BCTX
BCTX Stock Chart & Stats
$7.28
-$0.02(-3.38%)
At close: 4:00 PM EST
$7.28
-$0.02(-3.38%)
Day’s Range― - ―
52-Week Range$3.60 - $98.20
Previous Close$0.41
Volume996.24K
Average Volume (3M)71.25K
Market Cap
$27.68M
Enterprise Value$3.38M
Total Cash (Recent Filing)$10.18M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.38
Shares Outstanding7,250,487
10 Day Avg. Volume65,395
30 Day Avg. Volume71,255
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-45.89
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt provides durable financial flexibility for a cash‑burning clinical biotech. Without interest burdens the firm can prioritize R&D and partnerships, reducing bankruptcy risk versus highly leveraged peers and preserving optionality to time external raises or strategic deals.
Clinical-stage Immuno-oncology PipelineA focused immuno‑oncology program (Bria‑IMT and combination regimens) targets a structurally attractive market with durable unmet need. Clinical-stage assets can create long‑term value via trial readouts, partnering or licensing, offering fundamental upside if development milestones succeed.
Lean Operations And Modest Asset CushionA small workforce and modest asset base imply a lean cost structure and operational focus. This can stretch runway per dollar raised versus larger organizations, enabling targeted R&D spending and more nimble partnership or out‑licensing strategies when capital is constrained.
Bears Say
Pre-revenue With Widening LossesNo product revenue and materially larger TTM losses impose structural funding pressure. Sustained negative results lengthen time to self‑funding, making ongoing development contingent on external capital, which can slow programs and dilute existing shareholders over the medium term.
High Persistent Cash BurnLarge and persistent negative operating cash flow undermines a biotech's ability to complete clinical programs without financing or partnerships. Continued burn reduces runway, forces dilutive raises or unfavorable deals, and creates execution risk for multi‑stage development plans.
Shrinking Equity And Dilution RiskA steep decline in equity indicates prior dilution and accumulated losses, shrinking the balance sheet buffer. This increases the likelihood of further equity financing, which dilutes stakeholders and can constrain strategic choices, slowing long‑term value capture if trials require more capital.
BriaCell Therapeutics News
BCTX FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was $3.60 and its highest was $98.20 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is $27.68M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Mar 18, 2026 which is in 16 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Dec 11, 2025. The company reported -$4.384 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.384.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 7,250,487 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -$4.384 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.468%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in BCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―